Loading...
Market
What will be the primary source of Miplyffa's sales revenue by the end of 2025?
2
Resolution / Starting Odds
North America • 25%
Europe • 25%
Asia • 25%
Other • 25%
Zevra Therapeutics' official financial reports
Story
FDA Approves Zevra's Oral Drug Miplyffa for Niemann-Pick Disease Type C
Sep 20, 2024, 05:11 PM
The U.S. Food and Drug Administration (FDA) has approved Zevra Therapeutics' drug, Miplyffa, as the first oral medication to treat Niemann-Pick disease, type C (NPC). This approval, announced on September 20, 2024, marks a significant milestone for the treatment of this rare and fatal genetic disorder, which affects neurons. Parents and advocates have pushed for years for treatments for NPC, facing numerous setbacks before achieving this breakthrough.
View original story
Similar markets
Less than $50 million • 25%
$50 million - $100 million • 25%
$100 million - $150 million • 25%
More than $150 million • 25%
Bitcoin rewards program • 25%
Debit card transactions • 25%
Interest on Bitcoin holdings • 25%
Other financial services • 25%
Less than $25 million • 25%
$25 million to $50 million • 25%
$50 million to $75 million • 25%
More than $75 million • 25%
Seller Fees • 25%
Advertising • 25%
Subscription Services • 25%
Other • 25%
Advertising • 25%
Data licensing • 25%
Subscription services • 25%
Other • 25%
Less than 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
More than 75% • 25%
Ad Revenue • 25%
Subscription Revenue • 25%
Creator Revenue Sharing • 25%
Other • 25%
Licensing fees • 33%
Subscription fees • 33%
Advertising • 34%
Advertising • 25%
Subscription services • 25%
Data licensing • 25%
Other • 25%
Less than 1,000 • 25%
1,000 to 5,000 • 25%
5,000 to 10,000 • 25%
More than 10,000 • 25%